Please wait while we open this resource.
K
Lecture slides
Standard vs Double-Dose Dolutegravir in HIV-TB Co-Treatment
Dr. Mulinzi Solomon
PPTX202340 pages1001 KB
A journal club presentation reviewing a Lancet HIV 2023 study on the challenges and implementation of double-dose dolutegravir (DTG) co-treatment with rifampicin in patients with HIV and tuberculosis co-infection.
Sign in to open
Ask this resource
Answers use this document only.
Your first question is free.
More like this
Resources from the same specialty and type. Curated links will replace these when added.
Clinical Resources
Documents that extend or complement this resource.
Malaria Vaccine Implementation Guidelines
Same clinical topic · Infectious Diseases
HIV, TB, OIs final
Same clinical topic · Infectious Diseases
Haemoparasites
Same clinical topic · Infectious Diseases
Pharmacotherapy of infective endocarditis final
Same clinical topic · Infectious Diseases
PARASITIC INFECTIONS
Same clinical topic · Infectious Diseases
HIV RELATED OIS OTHER THAN TB
Same clinical topic · Infectious Diseases
ANTIRETROVIRAL THERAPY
Same clinical topic · Infectious Diseases
ART FAILURE AND IRIS
Same clinical topic · Infectious Diseases
HIV
Same clinical topic · Infectious Diseases